The FNIH Biomarkers Consortium is launching a three-year research partnership to develop new methods for analyzing digital images, which will lead to new ways to track a patient’s response to cancer therapy.
Learn about the achievements of the Biomarkers Consortium, which recently celebrated 10 years of collaboration, research and impact on regulatory science.
The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.